INC Research Augments Pediatric Clinical Trial Capabilities
News Feb 04, 2011
INC Research, LLC, has appointed Kathy Bohannon as its newest principal strategist, Pediatrics, who is responsible for developing the operational strategy and providing expertise in the design and execution of pediatric studies. She is joining an experienced team that provides complementary scientific and regulatory expertise for pediatrics trials.
"Kathy is enhancing our unique team model that leverages our deep therapeutic and regulatory expertise to develop a more holistic approach to pediatric trials," said John Potthoff, COO of INC Research. "Throughout her impressive career, Kathy has developed and managed pediatric trials across multiple therapeutic areas, clinical settings and pediatric age groups. She will be an invaluable addition to our leadership team as we raise our pediatrics services to a new level."
Bohannon comes to INC Research from her tenure at Premier Research Group where she was the senior director, Clinical Trial Management. In that role, she was project administrator responsible for all contractual, regulatory and project management activities within the Best Pharmaceuticals for Children Act - Coordinating Center (BPCA-CC).
Her pediatric experience also includes protocol and program development in compliance with FDA PREA, BPCA legislation, and the European Paediatric Regulation, with recent experience in support of pediatric acute and chronic pain. She received her BA in Biology from the University of Virginia and has completed graduate coursework in medicine, clinical research and chemistry.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019